RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bruce Shiramizu to Adolescent

This is a "connection" page, showing publications Bruce Shiramizu has written about Adolescent.
Connection Strength

0.462
  1. Shiramizu B, Mussolin L, Woessmann W, Klapper W. Paediatric non-Hodgkin lymphoma - perspectives in translational biology. Br J Haematol. 2016 05; 173(4):617-24.
    View in: PubMed
    Score: 0.063
  2. Knight TE, Knight SW, Kyono W, Thompson K, Hicks J, Shiramizu B. Peripheral Primitive Neuroectodermal Tumor and Neurofibromatosis Type 1 in an Adolescent Male. Pediatr Blood Cancer. 2016 07; 63(7):1310-1.
    View in: PubMed
    Score: 0.063
  3. Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
    View in: PubMed
    Score: 0.059
  4. Shiramizu B, Liang CY, Agsalda-Garcia M, Nagata I, Milne C, Zhu X, Killeen J, Berry JM, Goodman MT. Presence of high-risk human papillomavirus genotype and human immunodeficiency virus DNA in anal high-grade and low-grade squamous intraepithelial lesions. AIDS Res Hum Retroviruses. 2013 Jan; 29(1):178-81.
    View in: PubMed
    Score: 0.049
  5. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011 Jun; 153(6):758-63.
    View in: PubMed
    Score: 0.045
  6. Shiramizu B, Perkins SL, Bergeron S, Lones M, Kelly K, Weiner M, Cairo MS. Assessing immunoglobulin heavy chain rearrangements in pediatric CD20-positive and CD20-negative classic Hodgkin's disease. Clin Lymphoma. 2004 Dec; 5(3):184-9.
    View in: PubMed
    Score: 0.029
  7. Shiramizu B, Mick P. Epigenetic changes in the DAP-kinase CpG island in pediatric lymphoma. Med Pediatr Oncol. 2003 Dec; 41(6):527-31.
    View in: PubMed
    Score: 0.027
  8. Sabesan V, Cairo MS, Lones MA, Perkins SL, Morris E, Sposto R, Van De Ven C, Shiramizu B. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol. 2003 Feb; 25(2):109-13.
    View in: PubMed
    Score: 0.025
  9. Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021 10; 35(10):2994-2997.
    View in: PubMed
    Score: 0.023
  10. Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 2019 04; 185(2):374-377.
    View in: PubMed
    Score: 0.019
  11. Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
    View in: PubMed
    Score: 0.014
  12. Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol. 2013 Sep; 162(5):678-83.
    View in: PubMed
    Score: 0.013
  13. Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr; 27(5):1174-7.
    View in: PubMed
    Score: 0.012
  14. Payam A, Shiramizu B, Shikuma C, Milne C, Terada K, Kajioka E, Ka'opua LS, Cassel K, Chow D. HIV-associated anal dysplasia: experience from a multiethnic-HIV clinic in Hawaii. J Health Care Poor Underserved. 2011; 22(4 Suppl):16-22.
    View in: PubMed
    Score: 0.011
  15. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Feb; 52(2):177-81.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support